Syndax Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SNDX and other ETFs, options, and stocks.

About SNDX

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. 

CEO
Michael A. Metzger
CEOMichael A. Metzger
Employees
270
Employees270
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2005
Founded2005
Employees
270
Employees270

SNDX Key Statistics

Market cap
1.41B
Market cap1.41B
Price-Earnings ratio
-4.03
Price-Earnings ratio-4.03
Dividend yield
Dividend yield
Average volume
2.03M
Average volume2.03M
High today
$16.47
High today$16.47
Low today
$15.59
Low today$15.59
Open price
$15.77
Open price$15.77
Volume
1.77M
Volume1.77M
52 Week high
$22.50
52 Week high$22.50
52 Week low
$8.58
52 Week low$8.58

SNDX News

TipRanks 2d
Optimistic Buy Rating for Syndax Pharmaceuticals Driven by Promising Market Position and Growth Potential

Syndax Pharmaceuticals (SNDX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Stephen Willey. Elevate Your Investing Strategy: Take advanta...

Analyst ratings

100%

of 13 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own SNDX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.